Damage of hepatitis B virus (HBV) and hepatitis C virus (HCV)-infected hepatocytes is mediated by both a direct cytopathic effect of the viruses and by immunologic response of T -cells, However, other mechanisms such as oxidative stress, may also be involved in cellular damage. We conducted a study to investigate the status of superoxide dismutase activity (SOD) and the total antioxidant status (TAS) in a consecutive cohort of patients infected with HBV and HCV infections, including HBV patients in the chronic inactive state of the disease. The latter were included in an attempt to determine whether antioxidant status is affected even in cases where an obvious viral activity is absent. T AS and SOD were measured in 55 patients (43 HBV, 12 HCV) and 25 healthy controls. 17 out of 43 patients had chronic inactive HBV state, 15 had chronic hepatitis Band 11 had HBV-related cirrhosis. In the HCV group, 6 patients had chronic hepatitis C and 6 HCV-related cirrhosis. Erythrocyte SOD activity was determined in haemolysate from red blood cells using a kinetic spectrophotometer method. T AS was measured by a colorimetric assay. The mean TAS and SOD values in the total number of patients (1.20±O.12 mmol/L and 1040±255 Ulg Hb, respectively) were significantly lower (p<O.OOI) compared to healthy controls (1.57±O.13 mmol/L and 1491±420 D/g Hb), Comparisons between groups showed significantly lower (p<O.OOI) TAS and SOD values in each subgroup of patients compared to healthy controls. A significant positive correlation was found between TAS and SOD in the total number of patients (n= 55, p<O.OI), in the chronic hepatitis group (n=21, p=O.OI) and in the total group of HBV patients (n=43, p<O.OI). We demonstrated a significant reduced antioxidant capacity in patients with chronic HBV and HCV as indicated by low TAS and SOD. These findings were independent of the virological, biochemical and clinical status of the patients, including those with chronic inactive HBV state. This could suggest that the tissue-related consequences of oxidative stress might start from the inactive stage of liver viral diseases. However, our observations should be viewed with caution and need to be tested in a larger numbers of patients in order to determine prospectively whether these findings have pathophysiological and/or clinical significance.
Damage ofhepatitis B virus (HBV) and hepatitis C virus (HCV)-infected hepatocytes is mediated both by a direct cytopathic effect of the viruses and by immunologic effects of i.e. T-cells in their attempt to eliminate the viruses. However, recently there is increased evidence, which implicates the oxidative stress as an additional mechanism in the pathogenesis of several clinical and experimental conditions of chronic liver diseases, often in association with decreased antioxidant defences (1) (2) (3) (4) (5) . Under this context, free radicals provided by macrophages and other inflammatory cells appear to be crucial in hepatocellular damage and possibly in the formation of cirrhosis (1, (5) (6) (7) (8) . This can be attributed to a direct activation of hepatic stellate cells by the reacti ve oxygen species (ROS) and the reactive aldehydes arising from lipid peroxidation, leading to the transformation of hepatic stellate cells in myofibroblasts and the development of hepatic fibrosis and cirrhosis (9).
Increased production of ROS from activated phagocytes has already been shown in chronic HBV infection (8) . In addition, woodchuck hepatitis virus, a DNA virus that closely resembles HBV, can affect the host cell pro-oxidant /anti-oxidant balance by inhibiting the synthesis of antioxidant enzymes such as superoxide dismutase (SOD) and/or by increasing the production of pro-oxidants such as nitric oxide and the low-molecular weight iron compartment of the liver (1, 8) .
The presence of oxidative stress, as indicated by the determination of a wide range of pro-and anti-oxidant markers, has also been reported as a significant feature of HCV infection in a few recent studies (5-6, I 0-11). The enzymatic and non-enzymatic antioxidant defences include SOD, glutathione peroxidase, catalase, ascorbic acid, atocopherol, glutathione, b-carotene, vitamin A, etc. Both adequate levels and activities of these anti-oxidants are necessary for the survival of the organisms and their health (8) (9) (10) (11) (12) . With this notion in mind, we conducted a study to investigate the status of SOD, an enzymatic anti-oxidant, and the total anti-oxidant status (TAS) in the peripheral blood of a consecutive cohort of Greek patients with chronic HBV and HCV infections, including patients suffering from HBV but with repeatedly normal aminotransferases (chronic inactive state ofHBV). This group was included in an attempt to determine whether the antioxidant status is affected even in cases where an obvious activity of the viral disease is absent since, so far, it is difficult to distinguish between association and cause as well as between primary and secondary effects of a given virus on the antioxidant status.
MATERIALS AND METHODS

Subjects
Fifty-five patients (37 male, 18 female; median age: 58 years, range: 27-70 years) were studied. Among them 43 patients had chronic HBV and 12 had chronic HCV infection. Seventeen out of 43 HBV posruve patients had reactivity against hepatitis B surface antigen (HBsAg), antibodies to HBV e antigen (anti-HBe), repeatedly (> 6 months) normal aminotransferases and no viral replication as confirmed by the presence of low levels ofHBV-DNA (below 10' copies/ml) in their sera using a sensitive polymerase chain reaction assay (Cobas Amplicor HBV Monitor, Roche; cut off: 200 copies/ ml). According to the recent European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B held in September 2002, Geneva Switzerland, these patients were considered to be in the chronic inactive HBsAg state (13) . Fifteen out of 43 HBV patients had chronic hepatitis B and the remaining I I had HBV-related cirrhosis.
The diagnosis of chronic hepatitis B was based on clinical, laboratory and histologic evaluation as described by us previously with some modifications (I 4-I 5). Brief1y, all patients with chronic hepatitis B included in this study met the following criteria: (a) serological evidence of chronic infection with HB V for at least six months before taking part in this study; (b) active virus replication as defined by the detection ofHBV-DNA (> 10' copies/ml) using a commercially available PCR (Cobas Amplicor HBV Monitor, Roche); (c) elevated levels of alanine aminotransferase (ALT) at least twice the upper limit for at least six months before taking part in this study; and (d) histologically proven chronic hepatitis B without any sign of cirrhosis. The diagnosis ofHBV-related cirrhosis was also based on the criteria (a), (b), (c) and a liver histology compatible with cirrhosis. None of the HBV patients tested positive for antibodies to HCV (anti-HCV) or antibodies to HIV (anti-HIV) (Abbott Laboratories, Wiesbaden, Germany).
Six out of 12 HCV patients had chronic hepatitis C while the remaining 6 suffered from HCV-related cirrhosis. The diagnosis of chronic hepatitis C and HCV-related cirrhosis was based on clinical, laboratory and histologic evaluation as described by us previously (14) (15) (16) (17) (18) . None of the HCV patients was positive for HBsAg or anti-HIV.
Serum levels of aspartate aminotransferase (AST), AL T, v-glutamyl-traspeptidase (v-GT), and uric acid were determined using standard automated techniques. None of the patients had ever been under antiviral treatment in the past. In addition, none of them suffered from autoimmune, lymphoproliferative, malignant or other than the HBV or HCV chronic infectious disorders. We also studied 25 age and sex matched healthy volunteers in a ratio 2: I (two patients: one control). Their median age was 53 years (range: 36-68 years; 17 male, 8 female). None of the healthy controls had any serologic and/or clinical evidence of liver disease. In addition, all healthy controls tested negative for HBsAg, anti-HCV and anti-HIV. All subjects consented at the time of interview to participate in the study. The Local Ethical Committee of the University Hospital of Larissa approved the study protocol.
Determination of total anti-oxidant status (TAS) and superoxide dismutase (SOD)
Eight ml of whole blood were drawn in heparinized and non-heparinized tubes. Haemolysate from red blood cells was used for the determination of SOD activity, while serum samples were used for the T AS determinati on.
TAS was measured using a colorimetric assay (Randox, Antrim, UK). This method is based on the oxidation of substrate ABTS (2,2' -azino-di-[3ethylbenzthiazoline sulphonate]) by hydrogen peroxide in the presence of methmyoglobin. Twenty u.L of each serum sample were incubated with chromogen and substrate at 37°C and the suppression of colour production by the sample antioxidants was measured at 600 nm.
Erythrocyte SOD activity was determined using a kinetic spectrophotometer method (Randox, Antrim, UK). This method utilises xanthine oxidase to catalyze the oxidation of xanthine to uric acid and superoxide radicals. The superoxide radical reacts with I.N.T. (2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride) to form a red formazan dye. In the presence of SOD the formation of the dye is inhibited. The haemolysate was incubated at 37°C with xanthine, xanthine oxidase and I.N.T. and the inhibition of the dye formation was then measured at 500 nm.
Statistical Analysis
Results are expressed as mean ± standard deviation (SD). Data were analysed by Mann-Whitney U test (MWU), Kruskal-Wallis, analysis of variance (ANOVA) and Fisher PLSD test for comparison between groups, where applicable. Correlation coefficients were calculated by simple regression analysis (r) and non-parametric Spearman rank correlation (r) when appropriate. Twosided p values less than 0.05 were considered as statistically significant.
RESULTS
The mean values of AST, ALT, -y-GTand uric acid of the patients and controls are shown in Tab. I. There was no significant difference in uric acid levels between healthy controls and patients' groups either taking into account the patients as a total or in specific subgroups (Tab.I. Kruskal-Wallis, MWU tests). As expected, mean AST and ALT values were significantly increased in patients with chronic hepatitis B or C and HBV -or HCV -related cirrhosis compared to controls and the chronic inactive HBsAg state (Tab. I). Similar findings were also recorded for -y-GT values (Tab. I).
The due to significantly lower (p<O.OO I) TAS values in each specific subgroup of patients compared to healthy controls (Tab. II, Fig.l and Fig. 2) . In contrast, no significant differences were observed between the several subgroups of patients (Tab. II, Fig. I and Fig. 2 Fig. 3 and Fig. 4 ). Erythrocyte SOD activity levels did not differ significantly between the patients' subgroups (Tab.II. Fig.3 and Fig.4 ). T AS and SOD values did not correlate significantly with age, sex, uric acid, AST, ALT and )'-GT values either in each specific subgroup of patients or taking as a total the HBY andlor Hey patients (data not shown).
A significant positive correlation (r=0.41,
Tab. I. Mean values of uric acid, y-GT and aminotransferases in patients and controls.
n Uric acid (mg/dl) 'Y-GT (U/L)* AST (U/L)*** ALT (U/L)*** 
p<O.Ol) was found between TAS and SOD values
in the total number of HBV and HCV patients ( Fig.5 ). Taking into account the clinical status of the patients we found that the above positive correlation was obvious in the group of patients with chronic hepatitis Band C (n=21, r=0.54, p=O.Ol) and in the total HBV group (n=43, r=0.42, p<O.Ol). In the cirrhotic group there was a positive trend between T AS and SOD but without statistical significance (n= 17, r=0.46, p<O.l 0). In contrast, TAS and SOD values did not correlate significantly in the control group (r=O.l 0, p=0.27), in the group of chronic inactive HBsAg state (r=0.30, p=0.24) and the total group of HCV patients (r=0.36, p=0.28).
DISCUSSION
This study demonstrated a significantly reduced antioxidant capacity in patients chronically infected with HBV and HCV. The latter is indicated by the low levels ofTAS and erythrocyte SOD activity in all groups of patients irrespectively of their viral or clinical status, including patients with chronic inactive state of HB V infection. Our findings are in general in accordance with most of the reported studies, which have used different end points in an attempt to document an oxidative injury in patients with diverse chronic liver diseases (1, 2, (4) (5) (6) 8, (9) (10) (11) (12) 19, 20) . However, a few recent studies are reported concerning the antioxidant status in patients chronically infected with HBV and particularly in patients who are in the chronic inactive HBsAg state.
In contrast, there are studies where unexpected normal or even increased levels of TAS and/or SOD activity have been reported in different groups of patients with liver diseases (5, 8, 11, 21, 22) . For instance, Hadi Yasa et al (21) found reduced SOD acti vity in cirrhotic patients and normal thiobarbituric acid reacting substances (TBARS), Ozenirler et al (22) reported normal SOD levels in patients with chronic hepatitis and cirrhosis but decreased values in patients with inactive cirrhosis, while recently Jain et al (5) found decreased TAS levels in HCV-related cirrhosis but normal values in HCV non-cirrhotic patients. In addition, Irshad et al (11) reported the presence of reduced SOD levels in all patients with viral hepatic diseases irrespective of the viral type. However, the same investigators found comparable TAS levels between the majority of patients with acute, chronic or virus-related cirrhosis and healthy with the exception of patients with non-B, non-C, non-E acutehepatitis, non-B, non-C chronic hepatitis and HCV-related cirrhosis where significantly increased TAS values were detected (11) . These discrepancies between our findings and those reported in the above studies could be attributed to the different design of the studies, and to the possible interaction among different antioxidants in vivo that could also make the determination of each individual antioxidant less representative of the overall antioxidant status.
The effect of viruses on the pro-oxidant/antioxidant balance in host cells, including virally induced inhibition of antioxidant enzymes such as SOD and virally induced elevations in pro-oxidants such as nitric oxide, has already been reported (8, 19) . However, in most cases it is difficult to distinguish between primary and secondary effects of a given virus on the antioxidant status. In this study, the low SOD activity in HBV and HCV patients could be attributed to decreased synthesis caused directly or indirectly by the chronic viral infection. However, the significantly decreased levels of erythrocyte SOD activity and TAS in the chronic inactive HBsAg state may suggest a direct effect of the HBV. This is further supported by the findings in the present study, since SOD and TAS values did not correlate with biochemical or clinical parameters of activity in both HBV and HCV infections.
Viral infections are known to affect the prooxidant/anti-oxidant status by several ways. Virus-induced activation of macrophages is related to oxidative stress through the production ofROS and proinflamatory cytokines, such as tumor necrosis factor alpha, interleukin-6 and interleukin-l beta (5, 6, 8, 11, 12, 19, 23) . ROS production contributes to liver injury through apoptotic mechanisms and the induction of proinflammatory cytokines and chemokines from Kupffer cells that, in turn can further contribute to ROS production and reactive nitrogen species (1, 8, 12, 19, 23) . The consequent alteration of cellular redox state is enhanced by the related decrease of antioxidant and energy reserves. Our findings in chronic inactive HBsAg state could suggest that the above consequences may start from the inactive stage of liver viral diseases that means in patient-cases with no obvious viral replication or liver inflammation.
The reduced TAS values found in our study cannot support the possibility suggested by Irshad et al (11) . These investigators proposed that an adaptive rise of other antioxidants (e.g. uric acid) could act as a compensatory mechanism for the reduction of SOD activity. Thus they suggested that the final result of this mechanism could be the cause of keeping TAS within normal limits (11) . The reduced antioxidant capacity could be caused either by higher production of free radicals or by reduced antioxidant defence. The significant positive correlation that was observed in the present study between TAS and SOD values indicates that the second hypothesis is more likely. Total antioxidant capacity is generally under homeostatic control and a prominent decrease is a strong indication for the implication of oxidative stress during the process of chronic viral hepatitis infections (5, 6, 8, 12, 19, 20, 23, 24) . Recently, Okuda et al (20) have suggested that the HCV structural proteins (particularly the core protein) contribute to the oxidative stress in HCV infection. In addition, Jain et al (5) showed that this phenomenon is not just a feature of the late stage in cases with HCVrelated disease. Our findings in the chronic inactive HBsAg state further support the latter findings since oxidative stress appears to be present in cases without HBV replication or biochemical activity.
In conclusion, this study demonstrated a significant reduction in both erythrocyte SOD activity and TAS serum levels in patients chronically infected with HBV and HCV. Interestingly, these findings were independent of the virological, biochemical and clinical status of the patients, which means that the same reductions were detected even in patients who were in the chronic inactive HBsAg state. Although the precise molecular mechanisms of these effects have not been elucidated, our findings could suggest new therapeutic strategies against HBV and HCV irrespective of the clinical status of these diseases, since these viruses have thus far eluded attempts at conventional antiviral therapies, either because they integrate into host cell DNA, such as HBV, or because they mutate so rapidly as to escape immune surveillance, such as HCV. However, our observations should be viewed with caution and need to be tested in larger numbers of patients from many centres in order to confirm om findings (particularly the novel finding in the chronic inHCtivH BsAg state) and to determine prospectively whether they have pathophysiological fl,nd/Qr~linicijl significance.
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